The FDA awarded rare pediatric disease designation to Ziopharm Oncology's investigational gene therapy veledimex (Controlled IL-12) with Ad-RTS-hIL-12, a treatment for diffuse intrinsic pontine glioma, a type of brain tumor that accounts for about 10% to 15% of all brain tumors in children.
Brain tumor gene therapy nabs rare pediatric disease tag
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.